Table 1 Baseline, treatment and intervention characteristics of the 13 trial participants
Age, years, mean SD | 58 (8.0) |
|---|---|
Sex, male, n % | 10 (77) |
Smoking, past or current, n % | 7 (54) |
Weight, kg, mean SD | 78 (12) |
Education, post-secondary, n % | 6 (46) |
Karnofsky, 100, n % | 13 (100) |
Comorbidity, ≥ 1, n % | 3 (23) |
HNC tumor site | |
Oral cavity, n % | 4 (31) |
Oropharynx, n % | 6 (46) |
Supraglottic, n % | 1 (8) |
Unknown, n % | 2 (16) |
Tumor stage | |
III, n % | 3 (23) |
IVA, n % | 7 (54) |
IVB, n % | 3 (23) |
Total Cisplatin dose received at the time of final audiologic evaluation, mg, mean SD | 322 (145) |
Radiation dose received by the cochlea on the treated side at the time of final audiologic evaluation, grays, mean SD | 4.3 (4.5) |
Radiation dose received by the cochlea on the control side at the time of final audiologic evaluation, grays, mean SD | 7.0 (7.6) |
Time between preparation of STS gel and trans-tympanic injection, minutes, mean SD | 43.9 (27.5) |
Time between trans-tympanic injection and Cisplatin treatment, hours, mean SD | 20.6 (0.9) |